title: Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010.
authors.forename: Kathleen A
authors.initials: KA
authors.lastname: Fairman
authors.forename: Frederic R
authors.initials: FR
authors.lastname: Curtiss
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use; D016527:Drug Costs; D004348:Drug Labeling; D006297:Health Services Accessibility; D007349:Insurance, Health, Reimbursement; D007880:Legislation, Drug / Q000639:trends*; D008879:Midodrine / Q000009:adverse effects / Q000627:therapeutic use; D056687:Off-Label Use / Q000331:legislation & jurisprudence*; D055553:Prescription Drugs / Q000191:economics; D000069348:Quetiapine Fumarate; D014481:United States; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D055553:Prescription Drugs; D014662:Vasoconstrictor Agents; D000069348:Quetiapine Fumarate; D000068258:Bevacizumab; D008879:Midodrine